Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ARADIGM CORPARDM · Entity 155143 | Director | June 29, 2018 | July 03, 2018 |
| Matinas BioPharma Holdings, Inc.MTNB · Entity 8443 | Chief Development Officer | December 15, 2023 | December 16, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ARADIGM CORP
Report date June 29, 2018 · Filed July 03, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.45 · Expires 2028-06-29 | Direct | 50,000 |
Reported balance
After 2018-06-29 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-06-29 · Grant · Acquired 50,000 · Balance 50,000 F1: The shares underlying the option shall vest and become exercisable in four equal quarterly installments over one year beginning on June 29, 2018, subject to such individual continuing to be a Participant (as defined in the 2015 Equity Incentive Plan) on the relevant vesting dates. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying the option shall vest and become exercisable in four equal quarterly installments over one year beginning on June 29, 2018, subject to such individual continuing to be a Participant (as defined in the 2015 Equity Incentive Plan) on the relevant vesting dates.
Matinas BioPharma Holdings, Inc.
Report date December 15, 2023 · Filed December 16, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.25 · Expires 2033-12-15 | Direct | 1,300,000 |
Reported balance
After 2023-12-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-12-15 · Grant · Acquired 1,300,000 · Balance 1,300,000 F1: The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan. The option vests as to 25% of the shares on December 15, 2024 with the remaining shares to vest in equal monthly installments on the last day of each month over a period of 36 months commencing December 31, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan. The option vests as to 25% of the shares on December 15, 2024 with the remaining shares to vest in equal monthly installments on the last day of each month over a period of 36 months commencing December 31, 2024.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 15, 2023 Filed Dec 16, 2023 02:46 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | GrantStock Option (right to Buy) · Derivative | 1,300,000 | $0.00 Strike: $0.25 | $0.00 |
DisclosureSEC source: 0001493152-23-045167 · ownership.xml · derivative · entry 1 Matkovits Theresa · CIK 0001745393 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,300,000 Underlying: Common Stock · 1,300,000 shares Expires 2033-12-15 F1 · derivative.exercise_date: The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan. The option vests as to 25% of the shares on December 15, 2024 with the remaining shares to vest in equal monthly installments on the last day of each month over a period of 36 months commencing December 31, 2024. Read SEC document |
| December 20, 2022 Filed Dec 22, 2022 16:24 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | GrantStock Option (right to Buy) · Derivative | 625,000 | $0.00 Strike: $0.53 | $0.00 |
DisclosureSEC source: 0001493152-22-036243 · ownership.xml · derivative · entry 1 Matkovits Theresa · CIK 0001745393 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 625,000 Underlying: Common Stock · 625,000 shares Expires 2032-12-20 F1 · derivative.exercise_date: The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan. The option vests as to 25% of the shares on December 20, 2023 with the remaining shares to vest in equal monthly installments on the last day of each month over a period of 36 months commencing December 31, 2023. Read SEC document |
| December 14, 2021 Filed Dec 16, 2021 02:20 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | GrantStock Option (right to Buy) · Derivative | 500,000 | $0.00 Strike: $0.92 | $0.00 |
DisclosureSEC source: 0000905718-21-001607 · matinas_fm4dec142021.xml · derivative · entry 1 Matkovits Theresa · CIK 0001745393 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2031-12-13 F1 · derivative.exercise_date: The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan. The option vests as to 25% of the shares on December 14, 2022 with the remaining shares to vest in equal monthly installments on the last day of each month over a period of 36 months commencing December 31, 2022. Read SEC document |
| January 01, 2021 Filed Jan 4, 2021 23:30 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | GrantStock option (right to buy) · Derivative | 425,000 | $0.00 Strike: $1.36 | $0.00 |
DisclosureSEC source: 0001493152-21-000136 · ownership.xml · derivative · entry 1 Matkovits Theresa · CIK 0001745393 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 425,000 Underlying: Common Stock · 425,000 shares Expires 2030-12-31 F1 · derivative.exercise_date: The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan. The option vests as to 25% of the shares on January 1, 2022 with the remaining shares to vest in equal monthly installments over a period of 36 months commencing on February 1, 2022. Read SEC document |
| June 17, 2020 Filed Jun 19, 2020 21:30 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | GrantStock option (right to buy) · Derivative | 175,000 | $0.00 Strike: $0.82 | $0.00 |
DisclosureSEC source: 0001493152-20-011535 · ownership.xml · derivative · entry 1 Matkovits Theresa · CIK 0001745393 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,000 Underlying: Common Stock · 175,000 shares Expires 2030-06-16 F1 · derivative.exercise_date: The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan. Vesting is performance based and tied to achievement of positive topline ENHANCE-IT data (the "Milestone"). The option vests as to 1/3 upon achievement of the Milestone, with the remaining options to vest 1/3 on the first anniversary of such Milestone and 1/3 on the second anniversary of such Milestone. Read SEC document |
| January 01, 2020 Filed Jan 3, 2020 21:05 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | GrantStock option (right to buy) · Derivative | 350,000 | $0.00 Strike: $2.27 | $0.00 |
DisclosureSEC source: 0001493152-20-000118 · ownership.xml · derivative · entry 1 Matkovits Theresa · CIK 0001745393 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 350,000 Underlying: Common Stock · 350,000 shares Expires 2030-01-01 F1 · derivative.exercise_date: The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan. The option vests as to 25% of the shares on January 1, 2021 with the remaining shares to vest in equal monthly installments over a period of 36 months commencing on February 1, 2021. Read SEC document |
| February 11, 2019 Filed Feb 13, 2019 23:40 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | GrantOption (right to buy) · Derivative | 350,000 | $0.00 Strike: $1.08 | $0.00 |
DisclosureSEC source: 0000905718-19-000112 · matinasbiofm4_feb112019.xml · derivative · entry 1 Matkovits Theresa · CIK 0001745393 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 350,000 Underlying: Common Stock · 350,000 shares Expires 2029-02-10 F1 · derivative.exercise_date: The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan (the "2013 Plan"). The option vests as to 25% of the shares on February 11, 2020 with the remaining shares to vest in equal monthly installments over a period of 36 months commencing on March 1, 2020. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2013 Plan. Read SEC document |
| October 15, 2018 Filed Oct 16, 2018 20:31 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | GrantOption (right to buy) · Derivative | 350,000 | $0.00 Strike: $0.79 | $0.00 |
DisclosureSEC source: 0000905718-18-000853 · matinasbiofm4_oct152018.xml · derivative · entry 1 Matkovits Theresa · CIK 0001745393 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 350,000 Underlying: Common Stock · 350,000 shares Expires 2028-10-15 F1 · derivative.exercise_date: The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan (the "2013 Plan"). The option vests as to 25% on October 25, 2019, and the remaining 75% of the shares will vest in equal monthly installments over the following thirty-six (36) months commencing on November 25, 2019. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2013 Plan. Read SEC document |
| June 29, 2018 Filed Jul 3, 2018 17:26 UTC | ARADIGM CORP ARDM · Entity 155143 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $1.45 | $0.00 |
DisclosureSEC source: 0001123292-18-000853 · edgar.xml · derivative · entry 1 Matkovits Theresa · CIK 0001745393 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2028-06-29 F1 · derivative.exercise_date: The shares underlying the option shall vest and become exercisable in four equal quarterly installments over one year beginning on June 29, 2018, subject to such individual continuing to be a Participant (as defined in the 2015 Equity Incentive Plan) on the relevant vesting dates. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.